British guideline on the management of asthma. A national clinical guideline.

GUIDELINE TITLE
British guideline on the management of asthma. A national clinical guideline.

BIBLIOGRAPHIC SOURCE(S)
Scottish Intercollegiate Guidelines Network (SIGN), British Thoracic Society. British guideline on the management of asthma. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2009 Jun. 125 p. (SIGN publication; no. 101). [833 references]

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: Scottish Intercollegiate Guidelines Network (SIGN), British Thoracic Society. British guideline on the management of asthma. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2008 May. 121 p. (SIGN publication; no. 101). [766 references]

http://www.sign.ac.uk/new.html
This guideline will be considered for review in three years. Any amendments to the guideline in the interim period will be noted on the Scottish Intercollegiate Guidelines Network (SIGN) Web site.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

July 14, 2009 - Sirolimus (Rapamune), Cyclosporine (Sandimmune or Neoral and generics), Mycophenolate mofetil (Cellcept and generics), Mycophenolic acid (Myfortic): The U.S. Food and Drug Administration (FDA) is requiring the makers of certain immunosuppressant drugs to update their labeling to reflect that immunosuppressed patients are at increased risk for opportunistic infections, such as activation of latent viral infections, including BK virus-associated nephropathy.

abrir aquí para acceder al documento NGC AHRQ completo:
British guideline on the management of asthma. A national clinical guideline.